Abstract
Objective: The objective was to study the assessment of the possible cardiotoxic effect of imatinib using echocardiography.Methods: Prospective study included 50 patients that treated at the National Hematology Center of Al-Mustansiriya University from May 2008 to December 2009, echocardiography was used to measure the cardiac ejection fraction accurately, indices of ventricular ejection and relaxation and measurement of left ventricular internal diameter in diastole and (LVIDd) at baseline and after 12 months.Results: 24 (41%) were men and 26 (59%) were women. Their ages ranged from 18 to 74 years, with a median age of 36.8 years. At baseline, mean EF was 0.63±0.057 and after 12 months; mean EF was 0.64±0.068 (p>0.05). Mean peak emptying rate at baseline was 3.23±0.5 ED/s, and after 1 year was 3.21±0.5 ED/s (p>0.05). Time to peak filling rate at baseline was 144±26 ms, and after 1 year was 143±25 ms (p>0.05). There is a significant inverse trend for both LVIDd and LVID in systole (LVIDs) reduced as age increase; the female had significantly lower LVIDd and LVIDs compared to male.Conclusion: We find no evidence of significant impairment in cardiac function over 12 months of imatinib treatment. Advancing age associated with reduced cardiac performance for patients receiving imatinib.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
